A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

NCT06525935 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

469

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Overweight

Interventions

DRUG: Placebo
DRUG: Enicepatide

Sponsor

Carmot Therapeutics, Inc.

Collaborators

[object Object]